spacer
home > pmps > spring 2019 > the importance of product master data
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Importance of Product Master Data

By November 2019, wholesale distributors will be required to verify the serialised product identifiers for any saleable products that have been returned to them before they can be restocked and resold. With this new saleable returns verification requirement, the challenges of master data exchange for manufacturers will come to the fore.

To manage the scope, scale, and challenges of the saleable returns requirement, wholesalers and manufacturers must re-evaluate their current methods of exchanging product master data information.

The Scale of the Challenge

The national organisation representing primary wholesale distributors in the US, the Healthcare Distribution Alliance (HDA), executed analysis of saleable returns. This showed that approximately 60 million units of drug product are returned annually, with the majority of saleable returns caused by overstocking (1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dan Walles is the General Manager of Track & Trace and Compliance at TraceLink, where he brings more than 20 years of experience in product management, solution consulting, and service delivery to his role. He has focused exclusively on the needs of the life sciences industry for the past 15 years. Since joining TraceLink in 2010, Dan has been instrumental in educating customers on TraceLink’s Life Sciences Cloud and partner ecosystem to enable compliance and added business value through supply chain visibility and improved patient outcomes.
spacer
Dan Walles
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cidara Therapeutics Doses First Patient in Pivotal Phase 3 ReSPECT Trial of Rezafungin for Prevention of Invasive Fungal Disease in Patients Undergoing Allogeneic Blood and Marrow Transplantation

SAN DIEGO, Calif. & CAMBRIDGE, England, May 20, 2020 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, and Mundipharma today announced that the first patient has been dosed in its ReSPECT pivotal Phase 3 clinical trial evaluating the efficacy and safety of the company’s lead antifungal candidate, rezafungin, for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT). Rezafungin is a novel, once-weekly echinocandin being developed for both the treatment and prevention of severe fungal infections.
More info >>

White Papers
 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement